| Dr Agegnehu Tilahun Gebreyes, MD | |
|
3932 Covey Flush Ct Sw, Smyrna, GA 30082-3558 | |
| (202) 379-5463 | |
| Not Available |
| Full Name | Dr Agegnehu Tilahun Gebreyes |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 3932 Covey Flush Ct Sw, Smyrna, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124257845 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D73656 (Maryland) | Secondary |
| 207R00000X | Internal Medicine | 070889 (Georgia) | Secondary |
| 208M00000X | Hospitalist | 070889 (Georgia) | Primary |
| Entity Name | 24 On Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912956251 PECOS PAC ID: 5698688141 Enrollment ID: O20031216000444 |
News Archive
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers led by scientists at UC San Francisco and Washington University School of Medicine in St. Louis.
The research team, directed by Joseph Gleeson, M.D., Director of the Neurogenetics Laboratory at the UCSD School of Medicine and associate professor in the Department of Neurosciences, have identified a new gene that, when mutated, leads to JSRD. Their findings will be published on-line in advance of publication in the journal Nature Genetics.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.
A report issued by the Trust for America's Health is urging a revamp of state and local public health efforts to better integrate and focus prevention strategies.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Agegnehu Tilahun Gebreyes, MD 8954 Hospital Drive, Douglas, GA 30134 Ph: (678) 838-2585 | Dr Agegnehu Tilahun Gebreyes, MD 3932 Covey Flush Ct Sw, Smyrna, GA 30082-3558 Ph: (202) 379-5463 |
News Archive
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers led by scientists at UC San Francisco and Washington University School of Medicine in St. Louis.
The research team, directed by Joseph Gleeson, M.D., Director of the Neurogenetics Laboratory at the UCSD School of Medicine and associate professor in the Department of Neurosciences, have identified a new gene that, when mutated, leads to JSRD. Their findings will be published on-line in advance of publication in the journal Nature Genetics.
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.
A report issued by the Trust for America's Health is urging a revamp of state and local public health efforts to better integrate and focus prevention strategies.
› Verified 5 days ago